Connect Biopharma Appoints Autoimmune And Immunology Expert Chin Lee, MD, MPH As Chief Medical Officer

Connect Biopharma's research and development efforts are focused on next-generation immune modulators for the treatment of major autoimmune disorders and inflammation.

Connect Biopharma Appoints Autoimmune And Immunology Expert Chin Lee, MD, MPH As Chief Medical Officer
Photo by Connect Biopharma

Chin Lee, MD, MPH, has been named Chief Medical Officer of Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, effective March 1, 2022. Dr. Lee has over 15 years of experience in clinical research and development in the biopharmaceutical business. He has successfully led the submission of global regulatory files, including for FDA approvals in the United States, as well as product commercialization in a variety of autoimmune and immunological disease indications.

Dr. Lee stated, “I am honoured to join Connect Biopharma during this exciting time as they progress their pipeline of innovative development programs derived from their T cell-driven research. Connect is a leader in targeting immunological pathways, and I look forward to working with my new colleagues to discover and develop potential best-in-class therapies for inflammatory diseases.”

Connect Biopharma's co-founder and CEO, Zheng Wei, Ph.D, expressed his joy at the addition of Dr. Lee to the company's leadership team at this critical juncture. Dr. Lee's extensive drug development experience in inflammation and immunology, he believes, will help advance the company's clinical pipeline of potentially differentiated therapeutic candidates aimed at improving care and outcomes for millions of people suffering from inflammatory diseases around the world.

Source: Yahoo Finance, Globe Newswire